Stay updated on HBV Drug SB 9200 Safety & Efficacy Clinical Trial
Sign up to get notified when there's something new on the HBV Drug SB 9200 Safety & Efficacy Clinical Trial page.

Latest updates to the HBV Drug SB 9200 Safety & Efficacy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a Phase 2 study for SB 9200 in chronic Hepatitis B patients and the addition of a new revision number. The name 'Chelsea Macfarlane' has been retained as the Study Director.SummaryDifference52%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
Stay in the know with updates to HBV Drug SB 9200 Safety & Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HBV Drug SB 9200 Safety & Efficacy Clinical Trial page.